HAEMONETICS CORP
For the period ended Mar 29, 2025. Filed May 21, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed May 21, 2025
HAE$118.21-1.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
During the three months ended March 29, 2025, certain of our directors and officers (as defined under Rule 16a-1(f) under the Securities Exchange Act of 1934)adopted orterminated trading arrangements for the sale of shares of our common stock as follows:
| Trading Arrangement | |||||
|---|---|---|---|---|---|
| Name and Title · Action · Date(1) · Rule 10b5-1* · Non-Rule 10b5-1** · Number of Shares to be Sold(2) · Expiration Date(3) | |||||
| Stewart W. Strong, President, Global Hospital | Adoption | 2/14/2025 | X | 11,997(4) | 6/13/2025 |
| * Intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934. | |||||
| ** Not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934. | |||||
| (1) Reflects the fully-executed date of each trading arrangement, which may differ from the date of first execution by an officer or director. | |||||
| (2) The number of shares of common stock sold under each trading arrangement, if any, will be net of shares withheld for applicable tax obligations upon the vesting and/or exercise of covered securities as well as for payment of the exercise price upon the exercise of stock options, which amounts are not yet determinable. | |||||
| (3) Except as otherwise indicated by footnote, each trading arrangement expires upon the earlier of (a) completion of all authorized transactions thereunder and (b) the expiration date listed above. | |||||
| (4) Includes 8,246 target shares subject to a performance share unit (“PSU”) award previously granted to Mr. Strong on May 16, 2022. The actual number of shares to be earned under the PSU award, and subject to sale under this trading arrangement, may range from 0% to a maximum of 200% of the target award depending upon the Company’s total shareholder return relative to the components of the S&P MidCap 400 index during a three-year performance period from May 16, 2022 to May 15, 2025. | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.